Promising #EpsteinBarrVirus #EBV development @fredhutch.org: human monoclonal #antibodies #mAbs that block viral entry & protect humanized mice. Could be a big step toward preventing post-transplant lymphoproliferative disorder PTLD. #Immunology #TransplantMedicine
www.linkedin.com/posts/drmelv...

📣 The first site has been activated in the PIPELINE-RSV International trial & is now open for recruitment at St George's University Hospitals NHS Foundation Trust in London!

Congratulations to everyone involved in reaching this important milestone!

#RSV #Vaccination #MonoclonalAntibodies #mAbs

Rapid and selective characterization of antibody-drug conjugates in complex sample matrices by native affinity liquid chromatography-mass spectrometry Antibody-drug conjugates (ADCs) and other biopharmaceuticals require robust analytical methods to assess biotransformation in biological matrices. Current approaches often require off-line enrichme...

Full article: Rapid and selective characterization of antibody-drug conjugates in complex sample matrices by native affinity liquid chromatography-mass spectrometry #mAbs www.tandfonline.com/doi/full/10....

NEW WORKSHOP "Top-Down, Intact, and Native Mass Spectrometry in Biopharmaceutical Characterization" Feb.12, 2026. Speakers from #AstraZeneca, #Novartis, #Pfizer, #Genentech, #Sanofi, #JnJ, #Lilly and #NIBRT share stories and perspectives. > ctdp.org/biopharma-wo... #ADCs #mAbs #BsAbs #TsAbs #AAVs

FDA Issues Draft Guidance to Reduce Non-Human Primate Testing for Monoclonal Antibodies - OncoDaily FDA Issues Draft Guidance to Reduce Non-Human Primate Testing for Monoclonal Antibodies / cancer, FDA, Marty Makary, Non-Human Primate Testing, OncoDaily,

FDA Issues Draft Guidance to Reduce Non-Human Primate Testing for Monoclonal Antibodies

oncodaily.com/industry/fda-3

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MABs

Value profile for Malaria vaccines and monoclonal antibodies Malaria remains a leading cause of morbidity and mortality and is responsible for over 0.5 million annual deaths globally. During the first two decade…

While current malaria vaccines are already saving lives, new vaccines & #mAbs are being developed to accelerate malaria elimination.

A new @who.int-commissioned, PATH-led article in @elsevierlsj.bsky.social assesses the potential value of next-gen vaccines & mAbs: https://bit.ly/3X5qtiO

#MedSky

Value profile for Malaria vaccines and monoclonal antibodies Malaria remains a leading cause of morbidity and mortality and is responsible for over 0.5 million annual deaths globally. During the first two decade…

With #malaria #vaccines on the market, we're developing next-gen vaccines and monoclonal antibodies to bring us closer to #malariaeradication. Read about the @who.int-commissioned impact value assessment of malaria vaccines and prophylactic #mAbs in the pipeline: shorturl.at/CgG0J

MRC CASE/DTP

🚨 Applications are now open for fully funded PhD positions through the LSTM–Lancaster University MRC Doctoral Training Partnership for 2026/27 cohort. 🧪Several projects available under my supervision - details below
lstmed.ac.uk/mrc_dtp_case
#PhD #antibodies #mAbs #NTD #snakebite #infectiousdiseases

Single-residue engineering of lambda (λ) antibody light chains reduces conformational flexibility and enhances thermal stability. Computational and Structural Biotechnology Journal, DOI: https://doi.org/10.1016/j.csbj.2025.10.045

🔗 Single-residue engineering of lambda (λ) antibody light chains reduces conformational flexibility and enhances thermal stability. Computational and Structural Biotechnology Journal, DOI: doi.org/10.1016/j.cs...

📚 CSBJ: www.csbj.org

#MonoclonalAntibodies #mAbs #Immunology #MolecularDynamics

Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design AbstractBackground. As one of the most promising classes of next-generation antibody therapeutics, bispecific antibodies (bsAbs) have gained increasing att

New article alert: "Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design" from Fudan University.
academic.oup.com/abt/advance-...
#Antibody #Therapeutics #mAbs #Bispecific

Understanding the pharmacokinetic journey of Fc-fusion protein, rhIL-7-hyFc using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA Statement of Significance: The pharmacokinetic (PK) journey of Efineptakin alfa, a long-acting recombinant human interleukin-7, was explored through the co

Antibody Therapeutics (IF=4.5, published by Oxford University Press) Highlights "Understanding the pharmacokinetic journey of Fc-fusion protein, rhIL-7-hyFc using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA".
academic.oup.com/abt/article/...
#mAbs #Ab

Development, qualification, and application of a highly efficient and robust new peak detection workflow for the LC-MS peptide mapping multi-attribute method The multi-attribute method (MAM) by liquid chromatography-mass spectrometry peptide mapping has the potential to replace multiple conventional HPLC- and capillary electrophoresis-based purity/impur...

Full article: Development, qualification, and application of a highly efficient and robust new peak detection workflow for the LC-MS peptide mapping multi-attribute method #mAbs www.tandfonline.com/doi/full/10....

Directed protein engineering identifies a human TIM-4 blocking antibody that enhances anti-tumor response to checkpoint inhibition in murine colon carcinoma Statement of Significance: We developed a rapid antibody discovery program using directed-protein engineering to develop a first in class anti-human T-cell

New article “Directed protein engineering identifies a human TIM-4 blocking antibody that enhances anti-tumor response to checkpoint inhibition in murine colon carcinoma” contributed by Karla Frietze Miller, Ph.D. from Skunkworx Bio.

doi.org/10.1093/abt/...

#mAbs #TIM4 #Oncology

This opens a path to acid-switched / sweeping antibodies that recycle and neutralise multiple antigens without changing the paratope.

#sweeping #toxins #mAbs #acidswitching

Thanks to all co-authors & funders for making this possible!

"Connexin 43 hemichannels and related diseases"contributed by Yanfeng Zhang (AlaMab Therapeutics) and Jean X Jiang (University of Texas Health Science Center).
Free access of the full article through: academic.oup.com/abt/article/...
#Antibody #Therapeutics #mAbs

An integrated database of experimentally validated major histocompatibility complex epitopes for antigen-specific cancer therapy Statement of Significance: Current peptide-based cancer immunotherapy is challenged with the limited availability of immunogenic epitopes. To facilitate th

”An integrated database of experimentally validated major histocompatibility complex epitopes for antigen-specific cancer therapy“ contributed by researchers from Terasaki Institute for Biomedical Innovation.
academic.oup.com/abt/article/...
#Antibody #Therapeutics #mAbs #MHC

CDR clipping-induced heterodimerization: identification of a novel dimerization mechanism in a co-formulated antibody cocktail via a multifaceted mass spectrometry approach Co-formulated antibody cocktails are becoming an increasingly popular therapeutic class; however, they present analytical challenges over traditional single monoclonal antibody (mAb) formulations. ...

CDR clipping-induced heterodimerization: identification of a novel dimerization mechanism in a co-formulated antibody cocktail via a multifaceted mass spectrometry approach #mAbs www.tandfonline.com/doi/full/10....

Ion-exchange chromatography, capillary isoelectric focusing, and capillary zone electrophoresis coupled to mass spectrometry for charge variant analysis of monoclonal antibodies Monoclonal antibody (mAb) charge variant analysis, which ensures the quality of biopharmaceuticals, is primarily performed by either cation exchange chromatography (CEX), capillary isoelectric focu...

Ion-exchange chromatography, capillary isoelectric focusing, and capillary zone electrophoresis coupled to mass spectrometry for charge variant analysis of monoclonal antibodies #mAbs www.tandfonline.com/doi/full/10....

Cover of the ebook

#Medsky🧪 #Drugsdiscovery
The significance of #mAbs in drug discovery and development - freeebook to download

7915828.fs1.hubspotusercontent-na1.net/hubfs/791582...

Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab A sensitive and specific liquid chromatography-tandem mass spectrometry assay was developed for the quantification of chimeric aducanumab (chAdu), a therapeutic antibody targeting pathological amyl...

Full article: Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab #mAbs www.tandfonline.com/doi/full/10....

#Medsky🧪 #IDsky #microsky #immunosky #publichealth @systemsvirology.bsky.social et al Evaluated the cross-neutralization ability of 10 anti- #MERSCoV #mAbs against the #pseudoviruses with the spike proteins of 5 merbecoviruses known to use human dipeptidyl peptidase 4 (DPP4) as infection receptor.

Footprinting for fingerprinting: proof-of-concept for the use of hydroxyl radical protein footprinting for structural comparison studies Monoclonal antibodies (mAbs) require extensive physicochemical characterization to ensure product quality. The clinical and pharmacological properties of mAbs are linked to higher order structure (...

Full article: Footprinting for fingerprinting: proof-of-concept for the use of hydroxyl radical protein footprinting for structural comparison studies #mAbs www.tandfonline.com/doi/full/10....

Structure and function of therapeutic antibodies approved by the US FDA in 2024 Abstract. In 2024, the FDA approved 47 new molecular entities (NMEs), including 15 therapeutic antibody-based molecules, marking the 30th anniversary of th

New Publication Alert: "Structure and function of therapeutic antibodies approved by the US FDA in 2024" from William R Strohl.
academic.oup.com/abt/advance-...
#Antibody #Therapeutics #FDA #mAbs

“Monoclonal antibodies: The next frontier in disease prevention.” | Marc Elia “Monoclonal antibodies: The next frontier in disease prevention.” That headline says it all. And Aditya (Adi) Natu is right—and the frontier is here. The question now is whether we are able to cros...

Check out Marc Elia’s post about #mAbs:

www.linkedin.com/posts/marc-e...

Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors Statement of significance Many ADCs have unacceptable toxic effects, slowing their development progress. We describe the effects of ADC molecule structures

New Publication Alert: "Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors" from Chinese Academy of Sciences.
Free Access of Full text article through: academic.oup.com/abt/article/...
#Antibody #Therapeutics #ADC #mAbs

Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality Statement of Significance: FcγR polymorphisms influence therapeutic antibody efficacy by altering receptor expression and immune responses. This review hig

New Publication Alert: "Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality" from Food and Drug Administration.
Free access to full text article through: academic.oup.com/abt/article/...
#Antibody #Therapeutics #mAbs #Bioassay

New Publication Alert: "A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy" from Convalife Pharmaceuticals.
Free access of full text article through:academic.oup.com/abt/advance-article/doi/...
#Antibody #mAbs

Matching placebo development for injectable biologics—a practical tutorial AbstractBackground. In drug development, placebo-controlled trials are vital for assessing treatment efficacy. Developing a suitable placebo for injectable

New Publication Alert: “Matching placebo development for injectable biologics—a practical tutorial” contributed by Yunsong Li from WuXi Biologics.
Free access to the article through academic.oup.com/abt/advance-...
#Antibody #Therapeutics #mAbs

Antibody Therapeutics | Oxford Academic Launching in 2018, Antibody Therapeutics will publish the latest advances and challenges in the discovery, research, development, manufacturing and methodology of therapeutic antibodies for the global...

As a peer-reviewed and open access journal published by Oxford University Press, Antibody Therapeutics provides a forum for latest advances and challenges of therapeutic antibodies. The journal has been indexed by ESCI, Scopus (CiteScore=8.7) and PubMed Central.
academic.oup.com/abt
#Antibody #mAbs